Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Harmony Biosciences Hldgs is supported by a durable commercial base in WAKIX, with 2026 net revenue guidance reaffirmed at $1.00 billion–$1.04 billion versus a $1.03 billion FactSet consensus, while 2Q26 momentum included +450 net patients and 8,950 average patients on treatment. Its outlook is further strengthened by a credible pipeline that spans BP-205, EPX-100, pitolisant GR and HD, and ZYN002, giving the company multiple shots at growth across rare neurological and broader CNS indications. The planned CEO transition appears orderly rather than disruptive, and the company’s emphasis on preserving WAKIX exclusivity, expanding access, and advancing key data readouts through 2027 supports a positive fundamental view.

Bears say

Harmony Biosciences Hldgs is exposed to meaningful concentration risk because Wakix remains the key growth engine, so any slowdown in new patient additions or fresh competition in the sodium oxybate market could materially pressure revenue momentum. Its pipeline offers only partial diversification, and the cited risks around unsuccessful clinical trials in PWS, DM1, DS/LGS, and Fragile X, plus the possibility of earlier-than-expected generic pitolisant competition, weaken confidence in future growth durability. Although a long 25 hr half life and clean safety profile may support dosing versus oveporexton, the balance of evidence still points to execution and competitive risks outweighing upside.

HRMY has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Buy consensus rating as of Oct 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.